Clinical Trials Browser

Phase 2 × Platinum Compounds × 1 year × Clear all

NCT06465329 2026-02-12

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04585477 2026-02-10

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06769126 2026-01-22

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

NSCLC

NCT07340164 2026-01-14

TROY

Phase 2 Not yet recruiting

Ovarian Neoplasms, Recurrence

NCT04966676 2026-01-08

ATLAS

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT07295132 2025-12-19

RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)

Phase 2 Not yet recruiting

Ovarian Cancer Recurrent

NCT04765709 2025-12-16

BRIDGE

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT06623656 2025-10-23

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Phase 2 Recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07084610 2025-08-22

Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06986057 2025-05-22

Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms

NCT06234748 2025-05-13

ARTHOUSE

Phase 2 Active not recruiting

Oropharyngeal Neoplasms

NCT06908733 2025-04-03

Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung